Submission of Final Documents

Once an II-SR study has concluded, an investigator must complete and submit to Takeda via the takeda-iisr.com website a Final Document (FD) (e.g., final report, abstracts, posters and/or manuscripts, as applicable) resulting from the investigator's II-SR study.

Documentation required for submission of final document(s) to Takeda:

• Completed Final Document screens in the Takeda website
• Copies of draft final document(s) prior to their submission for publication

Study Closeout Notifications

Notify the appropriate parties of study closure:

Clinical studies: IRB and study results to http://www.clinicaltrials.gov

Non/pre-clinical studies: ACUC

Resource Request Accountability

Funding: Upon completion of the last milestone set forth in the Study Agreement (e.g., presentation or abstract and/or manuscript), the investigator must submit to Takeda a final payment requested, via the Takeda website.

Clinical/Drug Supplies: Upon completion of the final milestone set forth in the Study Agreement the Investigator must document, via the Takeda online website system, the return and/or destruction of any remaining supplies.

Contact Information

Takeda Pharmaceuticals North America, Inc.
One Takeda Parkway
Deerfield, IL 60015
224-554-6500
www.tpna.com


Thank you for your interest in Takeda's II-SR program.